Clarify the Role of Vivjoa for Recurrent Yeast Infections
September 2022
New oral Rx Vivjoa (oteseconazole) will be the first med approved for managing recurrent vulvovaginal candidiasis.
But this azole is only for patients with 3 or more yeast infections per year who are postmenopausal or permanently infertile.
Vivjoa is teratogenic in animals...and can stay in the body for up to 2 YEARS. So for now, it shouldn’t be used in ANY patient of childbearing potential, even those on contraceptives.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote